27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Analyst Stock Ratings Upgrades

Analyst upgrades are typically bullish for a stock. When there is a stock upgrade, the analysts who rate the stock feel better about the company's future and typically either recommend someone holds or buys the stock. Updated 05/09/2024

No data available to display
date
▲▼
ticker
▲▼
Buy Now
Company
▲▼
Current price
▲▼
Upside/Downside
▲▼
Analyst Firm
▲▼
Analyst & % Accurate
▲▼
Price Target Change
▲▼
Rating Change
▲▼
Previous / Current Rating
▲▼
Get Alert

Recent Analyst Stock Rating Upgrade News

Raymond James Upgrades Cheesecake Factory to Outperform, Announces $42 Price Target
Raymond James analyst Brian Vaccaro upgrades Cheesecake Factory (NASDAQ:CAKE) from Market Perform to Outperform and announces $42 price target.
Morgan Stanley Upgrades Editas Medicine to Equal-Weight, Announces $7 Price Target
Morgan Stanley analyst Matthew Harrison upgrades Editas Medicine (NASDAQ:EDIT) from Underweight to Equal-Weight and announces $7 price target.
Affirm Holdings Selloff Is 'Baffling': Analysts Dive Into Financial Results
Affirm Holdings (AFRM) stock rises after reporting strong fiscal Q3 results amid exciting earnings season. Analysts have mixed takeaways.
Shopify Profitability Remains A Concern, 5 Analysts Offer Commentary On Q1 Earnings
Shopify gross profit margins are expected to contract in the second quarter, one analyst says. The company's first-quarter beat was "modest."
JP Morgan Upgrades Affirm Holdings to Overweight, Raises Price Target to $43
JP Morgan analyst Reginald Smith upgrades Affirm Holdings (NASDAQ:AFRM) from Neutral to Overweight and raises the price target from $41 to $43.
Roth MKM Upgrades Laird Superfood to Buy, Raises Price Target to $4.5
Roth MKM analyst George Kelly upgrades Laird Superfood (AMEX:LSF) from Neutral to Buy and raises the price target from $1.3 to $4.5.
Wedbush Upgrades CytomX Therapeutics to Outperform, Raises Price Target to $8
Wedbush analyst Robert Driscoll upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Outperform and raises the price target from $3 to $8.
Needham Upgrades SiTime to Buy, Announces $130 Price Target
Needham analyst Quinn Bolton upgrades SiTime (NASDAQ:SITM) from Hold to Buy and announces $130 price target.
B of A Securities Upgrades Fox to Buy, Raises Price Target to $40
B of A Securities analyst Jessica Reif Ehrlich upgrades Fox (NASDAQ:FOXA) from Neutral to Buy and raises the price target from $34 to $40.
Cantor Fitzgerald Upgrades EVgo to Overweight, Announces $4 Price Target
Cantor Fitzgerald analyst Andres Sheppard upgrades EVgo (NASDAQ:EVGO) from Neutral to Overweight and announces $4 price target.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free